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“Beta agonists” refers to a family of compounds that include synthetic 
beta-adrenergic agonists which are similar to catecholamines. Beta- ago-
nists, thus, are involved in different metabolic actions. The beta-agonists 
of interest are compounds that decrease anabolism of lipids and allow 
greater anabolism of protein. These types of beta agonists are in line with 
present production goals of producing more lean and less fat.
At the present time, the beta agonists that are of interest are racto- 
pamine, salbutamol, clenbuterol, cimaterol and L-6449,969. Activity of 
these compounds covers several species, including beef cattle, swine and 
sheep. While none of these have yet been approved for use commercially, 
administration has been through the feed in studies conducted.
Early studies indicated clenbuterol was effective in reducing fat and in-
creasing lean in cattle and sheep, but it is no longer being considered as a 
potential growth regulator.
Recent studies with cimaterol and ractopamine indicate potential for 
swine with some responses in cattle and sheep. Studies with swine indicate 
ractopamine and cimaterol are effective means of reducing fat deposition 
and enhancing lean pork production.
One of the concerns about using products like beta agonists is that they 
will dramatically increase the quantity of feed, especially protein, required 
by swine. This cost increase could conceivably offset any benefit from us-
ing the products. However, current research has indicated that elevated 
dietary protein was not necessary to achieve an increase in carcass lean-
ness. Other research has found an increase in efficiency of feed utilization 
by swine receiving ractopamine, whereas, cimaterol had no effect on feed 
utilization. Together, this information demonstrates that, at least with 
ractopamine, the increase in carcass leanness will not require additional 
dietary protein, and may reduce the total feed requirements to produce a 
unit of meat by finishing swine.
A summary of six beef cattle trials with ractopamine fed the last 38 to 46
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days before slaughter, indicated improved average gain (18.4 percent) and 
decreased feed to gain (15.7 percent) with a slight reduction of 4.9 percent 
carcass percent fat and an increase of 2.5 percent carcass percent protein.
Beta agonists allow the restriction of fat during the growing and finish-
ing period of animals. With less production of fat, a more desirable pro-
tein product can be produced. The producer of should benefit the most 
from beta agonists since these compounds should reduce the cost of pro-
duction.
The consumer, whether at home or at a restaurant, determines what 
technologies are ultimately used in production of lean red meat. Presently, 
the consumer prefers lean red meat to higher levels of fat in the meat, but 
the consumer has equated tenderness to fat levels in red meat. Technolo-
gies such as beta agonists offer the potential to produce a quality protein 
product that meets consumer demands at a lower production cost.
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